David King, MD
Medical Oncology · Fridley, MNNPI 1417049396
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (47.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by AbbVie at 47.0% of the total. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.
Across 4 payments — averaging $63.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$120
- Mirati Therapeutics, Inc.$109
- Acrotech Biopharma Inc.$14
- Gilead$12
Across 48 payments — averaging $6645.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$170K
- Mirati Therapeutics, Inc.$96K
- E.r. Squibb & Sons, L.L.C.$32K
- Merck$20K
- Amgen$628
What the payments were for
- Grants$12047%
- Food & beverage$10943%
- Education$2610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $120 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$255 in reported general payments places this provider in the 35th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 25 | $555,285 |
| Lenalidomide | 40 | $499,327 |
| IbrancePalbociclib | 29 | $456,462 |
| CalquenceAcalabrutinib Maleate | 31 | $405,045 |
| XtandiEnzalutamide | 26 | $362,457 |
| RevlimidLenalidomide | 23 | $353,240 |
| ImbruvicaIbrutinib | 18 | $218,584 |
| ErleadaApalutamide | 12 | $171,372 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $128,285 |
| JaypircaPirtobrutinib | 12 | $123,264 |
| Abiraterone Acetate | 115 | $103,222 |
| XareltoRivaroxaban | 31 | $34,936 |
| EliquisApixaban | 30 | $23,376 |
| CreonLipase/Protease/Amylase | 11 | $22,232 |
| OxycontinOxycodone Hcl | 13 | $20,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $120 | $22,23211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 133 medical oncology providers in Minnesota.
Other medical oncology in Fridley
- Amy KrieMinneapolis$907K
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Noel LaudiCoon Rapids$274K
- Emmanuel AntonarakisMinneapolis$260K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.